Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain
June 27 2022 - 8:30AM
Artelo Biosciences,
Inc.
(Nasdaq: ARTL), a
clinical-stage pharmaceutical company focused on modulating
lipid-signaling pathways to develop treatments for people living
with cancer, pain, and neurological conditions, announced that
Professor Saoirse O’Sullivan, Vice President of Translational
Sciences at Artelo Biosciences, presented new research results
entitled, “Discovery and Preclinical Evaluation of a Novel
Inhibitor of FABP5, ART26.12, Effective In Chemotherapy-Induced
Pain,” during the opening oral session of the International
Cannabinoid Research Society (ICRS) Symposium.
“Our pre-clinical research showed that chronic, oral treatment
with ART26.12, our lead FABP5 inhibitor, was effective at both
preventing and treating both oxaliplatin and paclitaxel-induced
pain sensitivity without any sedating effects,” said Professor
Saoirse O’Sullivan. “In the prevention studies, ART26.12 also
minimized the acute weight loss caused by oxaliplatin. These
results support further development of ART26.12 in neuropathy
associated with chemotherapy and other neuropathies,” continued
Professor O’Sullivan.
Chemotherapy-Induced Peripheral Neuropathy, also known as CIPN,
is a common and often painfully debilitating complication of cancer
therapies, sometimes resulting in reduction or cessation of
treatment. For some cancer patients, CIPN may persist long after
chemotherapy is stopped. In pre-clinical models of CIPN, inhibition
of fatty acid binding protein 5 (FABP5) has demonstrated positive
activity in analgesia, ameliorating effects of CIPN, a condition
for which no currently approved treatment exists.
“Development of therapeutics for CIPN represents an attractive,
new opportunity for Artelo’s FABP5 inhibitors,” said Gregory D.
Gorgas, President and Chief Executive Officer of Artelo
Biosciences. “While we continue to develop our inhibitors to FABPs
in cancer and anxiety, based on these latest research findings in
CIPN, we intend to meet with the FDA for pre-IND consultation on
ART26.12 before the end of this year.”
The ICRS Symposium is being held at the Bailey Allen Hall at the
National University of Ireland, Galway, from June 25-30, 2022.
About ART26.12Fatty Acid Binding Proteins
(FABPs) are a family of intracellular proteins that chaperone
lipids including endocannabinoids and fatty acids. Various
inhibitors of FABPs may be particularly useful for the treatment of
specific cancers, neuropathic and nociceptive pain, and anxiety
disorders. ART26.12, Artelo’s lead FABP inhibitor compound, is a
selective inhibitor of FABP5. While developing our lead molecule
for Chemotherapy-Induced Peripheral Neuropathy, additional
compound(s) from our extensive library of potent and selective
inhibitors of FABPs have been identified and selected for
advancement towards regulatory-enabling studies in cancer and other
areas of high-unmet need where inhibition of FABPs show significant
promise.
About Artelo Biosciences Artelo Biosciences,
Inc. is a clinical stage pharmaceutical company dedicated to
the development and commercialization of proprietary therapeutics
that modulate lipid-signaling pathways including the
endocannabinoid system. Artelo is advancing a portfolio of broadly
applicable product candidates designed to address significant unmet
needs in multiple diseases and conditions, including anorexia,
cancer, anxiety, pain, and inflammation. Led by proven
biopharmaceutical executives collaborating with highly respected
researchers and technology experts, the company applies leading
edge scientific, regulatory, and commercial discipline to develop
high-impact therapies. More information is available
at www.artelobio.com and Twitter: @ArteloBio.
About the International Cannabinoid Research
SocietyThe International Cannabinoid Research
Society (ICRS) is the premier global scientific association
with more than 650 international members from 40 countries, all
active researchers in the field of endogenous, plant-derived, and
synthetic cannabinoids and related bioactive lipids. In addition to
acting as a source for impartial information on cannabis and the
cannabinoids, the main role of the ICRS is to provide an open forum
for researchers to meet and discuss their research. Interested
parties may follow @ICRS_Society and @sciencesaoirse on
Twitter and use #ICRS2022 for the latest meeting
updates.Forward Looking StatementsThis press
release contains certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934 and Private Securities
Litigation Reform Act, as amended, including those relating to the
Company’s product development, clinical and regulatory timelines,
market opportunity, competitive position, possible or assumed
future results of operations, business strategies, potential growth
opportunities and other statement that are predictive in nature.
These forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management’s current beliefs and
assumptions. These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
“expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company’s filings with the
Securities and Exchange Commission, including our ability to raise
additional capital in the future. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise, except to the extent required by
applicable securities laws.
Investor Relations Contact:Crescendo
Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Apr 2023 to Apr 2024